Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
暂无分享，去创建一个
T. Miller | T. Kipps | J. Gabrilove | Jennifer R. Brown | D. Mahadevan | J. Burger | B. Hill | A. Azaryan | J. Foran | K. Kelly | P. Barr | J. Sharman | M. Schreeder | P. Nava-Parada | W. Harb | J. Mei | Evelyn Barnett | J. Marine | Shuo Ma